Global review confirms mRNA vaccines are safe, effective and full of promise
A new global review in The Lancet concluding that mRNA COVID-19 vaccines are safe, effective, and promising for future applications (like flu and cancer treatments) prompts intense debate over how that squares with personal experiences, reported side effects, and evolving trial data. Commenters argue over absolute versus relative risks (e.g., myocarditis from infection vs. vaccination), the ethics and fallout of mandates, and the deep mistrust of governments, regulators, and pharmaceutical companies that has grown from past policy failures and pandemic-era messaging. Many agree that mRNA remains a powerful technology but differ sharply on whether current evidence, transparency, and institutions are enough to justify confidence.
Political and policy context
- Many comments veer into US politics: appointments of vaccine‑skeptic health officials, “loyalty over competence,” and contrasts between earlier and current administrations.
- Debate over who deserves credit or blame for fast‑tracking COVID vaccines and for decisions on gain‑of‑function research funding and pandemic preparedness.
- Some argue corporate welfare for pharma has become a partisan issue.
Effectiveness and goals of mRNA COVID vaccines
- Multiple commenters stress vaccines were primarily to reduce severe disease, hospitalization, and death, not to guarantee zero infection.
- Others push back, citing early official statements that implied prevention of infection and transmission, calling later reframing “gaslighting.”
- Several references and anecdotes claim large reductions in hospitalization and mortality among vaccinated populations.
Side effects, myocarditis, and blood clots
- Broad agreement that side effects exist but are rare; myocarditis in young males is discussed heavily.
- Links are shared showing myocarditis/pericarditis risk from COVID infection is much higher than from mRNA vaccination, though critics argue some studies focus on older cohorts or undercount asymptomatic cases.
- Adenovirus‑vector vaccines (e.g., AstraZeneca, J&J) are distinguished from mRNA, with documented rare clotting syndromes leading to their withdrawal or restriction.
- “Calamari”-like clots and embalmer reports are raised; others demand data and label this as unsubstantiated or driven by social media.
Mandates, ethics, and risk tradeoffs
- Strong resentment from some who felt coerced by job mandates, especially younger or previously infected people.
- Others argue all public policy is a trolley‑problem‑like tradeoff between individual risk and collective benefit; vaccine deaths must be weighed against many more preventable COVID deaths.
- Disagreement over whether mandates were justified given non‑sterilizing vaccines, and whether they caused long‑term damage to trust.
Trust, transparency, and institutions
- Repeated theme: distrust of governments, regulators, and “big pharma,” fueled by past scandals, perceived propaganda, and censorship.
- Some say no amount of new reviews will sway committed skeptics; others call for more transparent risk numbers, better communication, and open debate rather than suppression.
mRNA platform potential
- Several are excited about applications beyond infectious disease, especially personalized cancer vaccines and faster flu vaccines, enabled by the pandemic‑driven manufacturing scale‑up.
- A minority points to curated databases of papers on adverse effects as evidence that safety and “full of promise” claims are not universally accepted.